Search

Abstract: The plasma membrane bound nucleoside triphosphate diphosphohydrolase (NTPDase)-1, 2, 3 and 8 are major ectonucleotidases that modulate P2 receptor signaling by controlling nucleotides’ concentrations at the cell surface. In this report, we systematically evaluated the effect of the commonly used P2 receptor antagonists reactive blue 2, suramin, NF279, NF449 and MRS2179, on recombinant human and mouse NTPDase1, 2, 3 and 8. Enzymatic reactions were performed in a Tris/calcium buffer, commonly used to evaluate NTPDase activity, and in a more physiological Ringer modified buffer. Although there were some minor variations, there were no major changes either in the enzymatic activity or in the profile of NTPDase inhibition between the two buffers. Except for MRS2179, all other antagonists significantly inhibited these ecto-ATPases; NTPDase3 being the most sensitive to inhibition and NTPDase8 the most resistant. Estimated IC50 showed that human NTPDases were generally more sensitive to the P2 receptor antagonists tested than the corresponding mouse isoforms. NF279 and reactive blue 2 were the most potent inhibitors of NTPDases which almost completely abrogated their activity at the concentration of 100μM. In conclusion, reactive blue 2, suramin, NF279 and NF449, at the concentrations commonly used to antagonize P2 receptors, inhibit the four major ecto-ATPases. This information may reveal useful for the interpretation of some pharmacological studies of P2 receptors. In addition, NF279 is a most potent non-selective NTPDase inhibitor. Although P2 receptor antagonists do not display a strict selectivity toward NTPDases, their IC50 values may help to discriminate some of these enzymes. [Copyright &y& Elsevier]

Beside calcification, the impact of ABCC6 deficiency on the vasculature remains unclear. We investigated arterial structure and function in Abcc6-/- mice, a model of the human Pseudoxanthoma Elasticum (PXE). Arterial calcium accumulation determined by atomic absorption spectrometry was 1.5 – to 2-fold higher in Abcc6-/- than in wild-type mice. Calcium also accumulated locally leading to a specific punctuated pattern. Abcc6-/- mesenteric arteries mounted on a wire myograph displayed slight increase in arterial vasoconstrictor tone in response to phenylephrine and thromboxane A2. Interestingly, myogenic tone (Bayliss effect) determined using a pressure myograph was significantly elevated in Abcc6-/- compared to wild type arteries. Arterial blood pressure was not significantly modified in Abcc6-/- animals, despite higher variability. These changes were accompanied with deregulated gene expression (RTqPCR) in both liver and resistance arteries. Old Abcc6-/- mouse mesenteric arteries expressed markers of both osteogenic (Runx2, opn) and chondrogenic lineage (Sox9, col2a1). Surprisingly Enpp1 and Alpl genes encoding ectonucleotide pyrophosphatase/phosphodiesterase 1 and alkaline phosphatase were deregulated within Abcc6-/- liver and this was corroborated with reduced alkaline phosphatase circulating levels in PXE patients. As a conclusion, scattered calcium depositions result from osteochondrogenic transdifferentiation of vascular cells. The lower elasticity and increased myogenic tone evidenced in aged Abcc6-/- mice suggest a reduced control of local blood flow, which in turn may alter vascular homeostasis. Our findings argue in favor of a deregulated arterial function and may help to decipher consequences of ABCC6 deficiency since PXE is a significant risk factor for small vessel disease and particularly ischemic stroke. [ABSTRACT FROM AUTHOR]

Hypertension is characterized by a hypertrophic remodeling of big arteries, increased tone in smallest, endothelial dysfunction and accompanied by oxidative stress, inflammation and fibrosis. Extracellular nucleotides, which are released under cellular stress, promote deleterious pathological responses (vasoconstriction, inflammation, vascular permeability) through P2 receptors activation although the contribution of purinergic signaling to cardiovascular pathologies remains to be established. Hydrolysis of these molecules is provided by nucleoside triphosphate diphosphohydrolases (NTPDases), especially NTPDase1 (CD39), highly expressed in the arterial wall. Together with ecto-5’nucleotidase (CD73), these enzymes generate vasoprotective adenosine (ADO anti inflammatory, vasodilatory). Using Apyrase (APY, soluble potato nucleotidase) treatment and CD39 deficient ( Entpd1-/- ) mice, we evaluated the potential benefit of nucleotides hydrolysis in experimental hypertension. After 12 days of AngII (1mg/kg/day) infusion, with or without APY (45U sc, 15U ip every 3 days), the increase in systolic blood pressure (SBP) and the hypertrophic aortic remodeling were significantly reduced in AngII/APY-treated mice compared to AngII-treated mice. Reversely, in Entpd1-/- mice treated with intermediate dose of AngII (0.5mg/kg/day) the increase in SBP was greater than in Entpd1+/+ mice. This was associated with exacerbated hypertrophic aortic remodeling. Interestingly, RT-qPCR revealed a decreased CD39 expression level in resistance arteries of AngII-treated mice and SHR rats, suggesting a role for the enzyme in hypertension. The role of CD39 as a regulator of arterial tone through the control of P2Y6 receptor activation is likely, although its contribution in the prevention of vascular inflammation remains to be investigated. Consequently, nucleotidases protect against high blood pressure and represent new therapeutic area in the treatment of hypertension. [ABSTRACT FROM AUTHOR]

Extracellular nucleotides are responsible for pleiotropic effects in the vasculature. Uracyl nucleotides are vasoactive and trophic agents and promote inflammation. The participation of specific P2 receptors in these effects remains undefined and their potential contribution in arterial hypertension is unknown. Objective To evaluate the contribution of the UDP receptor P2Y6 in hypertension in mouse. Methods Arterial contraction was evaluated using a wire myograph. Blood pressure was measured following nucleotides iv infusion and experimental hypertension was induced either by Angiotensine-II (Ang-II 1mg/kg/j) or DOCA-salt (1%) in uni-nephrectomized mice. Histological approaches, immunofluorescence and RTqPCR were used to evaluate the nature of vascular remodeling. Results P2Y6 displayed the highest arterial expression level among other P2Y receptors. Contraction of conductance (thoracic aorta) and resistance (mesenteric) arteries was abrogated in P2ry6-/- mice in response to UDP and UTP while other vasoconstrictor induced normal responses. P2Y6 receptor triggered a moderated intracellular calcium increase while RhoA (calcium facilitating pathway) activation was abrogated in P2ry6-/- mice. Both genetic deletion and pharmacological blockade of P2Y6 receptor abolished Ang-II-induced blood pressure increase (40 mmHg in wild type mice). By contrast, hypertensive response in DOCA-salt was equivalent in both genotypes. Following Ang-II treatment, P2ry6-/- mice developed a reduced arterial hypertrophic remodeling and fibrosis but equivalent immune cell recruitment/infiltration compared to wild type. These changes were corroborated to reduced mRNA expressions of TGFβ and NADPH oxidase subunits. Conclusions Vascular P2Y6 receptor contributes to exaggerated vascular tone, hypertrophy and fibrosis in the context of Ang-II-dependent hypertension. Its absence or pharmacological blockade limits vascular damages and prevents blood pressure increase associated to hypertension. [ABSTRACT FROM AUTHOR]

Background and aims Pseudoxanthoma elasticum (PXE; OMIM 264800 , prevalence 1/25,000 to 1/50,000) is an autosomal recessive multisystem disease due to deficiency in ABCC6, an ATP-binding cassette, sub-family C transporter. The PXE phenotype is mainly characterized by progressive ectopic calcification of connective tissues (namely skin, retinal Bruch's membrane and peripheral arteries) but the impact of PXE on bone structure is currently unknown. The present study sought to investigate bone mineralization and its potential link with vascular calcification in a large cohort of PXE patients with inherited mutations of the ABCC6 gene. Methods and results 96 patients (61 women) matching the PXE criteria participated in this study. Their clinical history and status and bone biological markers were collected. Bone mineral density (BMD) was measured by dual energy X-ray absorptiometry and expressed as T- and Z-scores. Osteoporotic fractures were identified by X-ray, and coronary (CAC) and lower limb arterial calcification (LLAC) scores were determined by CT scan. Results 44% of the women were menopausal. Osteopenia was disclosed in 46% (17 women) while 23% (9 women) exhibited osteoporosis, 3 with severe osteoporosis. Fractures of an osteoporotic nature were authenticated in 3 patients (1 woman). Markers of bone remodelling processes (CTX, BSAP and osteocalcin) were within the normal range for our laboratory standards. Severe vitamin D deficiency (< 25 nmol/L) was found in 15%, while 51% exhibited no vitamin D deficiency (vitamin D ≥ 50 nmol/L). LLAC and CAC scores were significantly higher in the patients with a low T- and/or Z-score, although this difference disappeared in multivariate analysis with age as a confounding factor. There was no significant difference in LLAC and CAC between PXE patients with and without osteoporotic fractures. There was no statistically significant association between BMD, LLAC and CAC and any of the bone remodelling factors. Conclusions This is the first report on the bone mineralization process in PXE patients. Our data shows that PXE patients are not markedly prone to exaggerated bone demineralization and fracture risk, and prevalence of osteoporosis remains within the normal range for the general population. Furthermore, the relationships between LLAC, but not CAC, and BMD with age are similar to those observed in the general population. Therefore, despite its pivotal role in ectopic calcification, ABCC6 deficiency does not interfere with the bone-vascular axis. The lack of PXE-related disturbances between BMD and arterial calcification also supports vitamin D supplementation in PXE patients with vitamin D deficiency. ClinicalTrials.gov Identifier: NCT01446393 . [ABSTRACT FROM AUTHOR]

Phosphoinositide (PI) 3-kinases play an important role in regulating the adhesive function of a variety of cell types through affinity modulation of integrins. Two type I PI 3-kinase isoforms (P110β and p110γ) have been implicated in Gi-dependent integrin αIIbβ3 regulation in platelets, however, the mechanisms by which they coordinate their signaling function remains unknown. By employing isoform-selective PI 3-kinase inhibitors and knock-out mouse models we have identified a unique mechanism of PI 3-kinase signaling co-operativity in platelets. We demonstrate that p110β is primarily responsible for G1-dependent phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2) production in ADP-stimulated platelets and is linked to the activation of Rap1b and AKT. In contrast, defective integrin αIIbβ3 activation in p110γ-/- platelets was not associated with alterations in the levels of PI(3,4)P2 or active Rap1b/AKT. Analysis of the effects of active site pharmacological inhibitors confirmed that P110γ principally regulated integrin αIIbβ3 activation through a non-catalytic signaling mechanism. Inhibition of the kinase function of PI 3-kinases, combined with deletion of p110γ, led to a major reduction in integrin αIIbβ3 activation, resulting in a profound defect in platelet aggregation, hemostatic plug formation, and arterial thrombosis. These studies demonstrate a kinase-independent signaling function for p110γ in platelets. Moreover, they demonstrate that the combined catalytic and non-catalytic signaling function of p110β and p110γ is critical for P2Y12/Gi-dependent integrin αIIbβ3 regulation. These findings have potentially important implications for the rationale design of novel antiplatelet therapies targeting PI 3-kinase signaling pathways. [ABSTRACT FROM AUTHOR]